These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36453541)

  • 1. Neuromyelitis optica spectrum disorder: pathophysiological approach.
    Mireles-Ramírez MA; Pacheco-Moises FP; González-Usigli HA; Sánchez-Rosales NA; Hernández-Preciado MR; Delgado-Lara DLC; Hernández-Cruz JJ; Ortiz GG
    Int J Neurosci; 2024 Aug; 134(8):826-838. PubMed ID: 36453541
    [No Abstract]   [Full Text] [Related]  

  • 2. Optic neuritis in neuromyelitis optica.
    Levin MH; Bennett JL; Verkman AS
    Prog Retin Eye Res; 2013 Sep; 36():159-71. PubMed ID: 23545439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders.
    Takai Y; Misu T; Suzuki H; Takahashi T; Okada H; Tanaka S; Okita K; Sasou S; Watanabe M; Namatame C; Matsumoto Y; Ono H; Kaneko K; Nishiyama S; Kuroda H; Nakashima I; Lassmann H; Fujihara K; Itoyama Y; Aoki M
    Brain; 2021 Sep; 144(8):2401-2415. PubMed ID: 33711152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
    Tradtrantip L; Asavapanumas N; Verkman AS
    Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
    [No Abstract]   [Full Text] [Related]  

  • 7. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury.
    Marignier R; Nicolle A; Watrin C; Touret M; Cavagna S; Varrin-Doyer M; Cavillon G; Rogemond V; Confavreux C; Honnorat J; Giraudon P
    Brain; 2010 Sep; 133(9):2578-91. PubMed ID: 20688809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid.
    Marignier R; Ruiz A; Cavagna S; Nicole A; Watrin C; Touret M; Parrot S; Malleret G; Peyron C; Benetollo C; Auvergnon N; Vukusic S; Giraudon P
    J Neuroinflammation; 2016 May; 13(1):111. PubMed ID: 27193196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies.
    Nicchia GP; Mastrototaro M; Rossi A; Pisani F; Tortorella C; Ruggieri M; Lia A; Trojano M; Frigeri A; Svelto M
    Glia; 2009 Oct; 57(13):1363-73. PubMed ID: 19229993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders.
    Tzartos JS; Stergiou C; Kilidireas K; Zisimopoulou P; Thomaidis T; Tzartos SJ
    PLoS One; 2013; 8(9):e74773. PubMed ID: 24086369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2.
    Hinson SR; Roemer SF; Lucchinetti CF; Fryer JP; Kryzer TJ; Chamberlain JL; Howe CL; Pittock SJ; Lennon VA
    J Exp Med; 2008 Oct; 205(11):2473-81. PubMed ID: 18838545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aquaporin-4 in Neuromyelitis Optica Spectrum Disorders: A Target of Autoimmunity in the Central Nervous System.
    Abe Y; Yasui M
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent progress in multiple sclerosis research: astrocytopathy in demyelinating diseases].
    Kira J
    Rinsho Shinkeigaku; 2010 Nov; 50(11):788-93. PubMed ID: 21921443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
    Sharma J; Bhatti MT; Danesh-Meyer HV
    Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.